Recent News

• 05.17.2026 - Seralutinib for the Treatment of Pulmonary Arterial Hypertension: Results From the Phase 3 PROSERA Trial
• 04.22.2026 - A Real-World Mixed Methods Analysis of Undertreatment and Delays in Therapy Escalation in Pulmonary Arterial Hypertension in the US

Recent Filings

• 05.18.2026 - EX-99.1 EX-99.1
• 05.18.2026 - PRE 14A Other preliminary proxy statements
• 05.18.2026 - 8-K Current report
• 05.18.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.15.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.24.2026 - DEF 14A Other definitive proxy statements
• 04.24.2026 - ARS Annual Report to Security Holders
• 04.24.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.09.2026 - 8-K Current report